Nevertheless, most of the reports on the improvement of the lipid profile, including modest reductions in LDL-C, total cholesterol, and triglycerides, come from clinical trials of GLP-1R agonists in patients with type 2 diabetes and the observed effects were exerted by exogenous, long-acting GLP-1 [37] (Sun 2015). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.